Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026)

Aytu Biopharma has reported Asset Writedowns and Impairment over the past 6 years, most recently at $800000.0 for Q4 2025.

  • Quarterly Asset Writedowns and Impairment rose 700.0% to $800000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 4.69% year-over-year, with the annual reading at $300000.0 for FY2025, 74.77% down from the prior year.
  • Asset Writedowns and Impairment was $800000.0 for Q4 2025 at Aytu Biopharma, up from $300000.0 in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $45.2 million in Q1 2022 and troughed at -$62.5 million in Q2 2022.
  • The 5-year median for Asset Writedowns and Impairment is $100000.0 (2021), against an average of -$338500.0.
  • Year-over-year, Asset Writedowns and Impairment soared 2784.62% in 2021 and then tumbled 1210.45% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $100000.0 in 2021, then fell by 18.0% to $82000.0 in 2022, then increased by 21.95% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then soared by 700.0% to $800000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Asset Writedowns and Impairment are $800000.0 (Q4 2025), $300000.0 (Q3 2025), and $100000.0 (Q2 2025).